{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Carnitine O-palmitoyltransferase : Questions médicales les plus fréquentes",
"headline": "Carnitine O-palmitoyltransferase : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Carnitine O-palmitoyltransferase : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-06",
"dateModified": "2025-04-02",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Carnitine O-palmitoyltransferase"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Carnitine acyltransferases",
"url": "https://questionsmedicales.fr/mesh/D002333",
"about": {
"@type": "MedicalCondition",
"name": "Carnitine acyltransferases",
"code": {
"@type": "MedicalCode",
"code": "D002333",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.050.350"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Carnitine O-palmitoyltransferase",
"alternateName": "Carnitine O-Palmitoyltransferase",
"code": {
"@type": "MedicalCode",
"code": "D002334",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Stephan Zierz",
"url": "https://questionsmedicales.fr/author/Stephan%20Zierz",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology, Martin-Luther-University Halle-Wittenberg, Ernst-Grube Str. 40, 06120 Halle (Saale), Germany."
}
},
{
"@type": "Person",
"name": "Yixin Chen",
"url": "https://questionsmedicales.fr/author/Yixin%20Chen",
"affiliation": {
"@type": "Organization",
"name": "Institute of Clinical Pharmacology and Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China."
}
},
{
"@type": "Person",
"name": "Huizhen Zhang",
"url": "https://questionsmedicales.fr/author/Huizhen%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Institute of Clinical Pharmacology and Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China."
}
},
{
"@type": "Person",
"name": "Min Huang",
"url": "https://questionsmedicales.fr/author/Min%20Huang",
"affiliation": {
"@type": "Organization",
"name": "Institute of Clinical Pharmacology and Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China."
}
},
{
"@type": "Person",
"name": "Huichang Bi",
"url": "https://questionsmedicales.fr/author/Huichang%20Bi",
"affiliation": {
"@type": "Organization",
"name": "Institute of Clinical Pharmacology and Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The Montreal Cognitive Assessment Test (MoCA) as a screening tool for cognitive dysfunction in fibromyalgia.",
"datePublished": "2022-06-08",
"url": "https://questionsmedicales.fr/article/35699063",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.55563/clinexprheumatol/3yxu6p"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Spectrum of Cognitive Dysfunction in Amyotrophic Lateral Sclerosis: An Update.",
"datePublished": "2023-09-27",
"url": "https://questionsmedicales.fr/article/37834094",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms241914647"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Confusion Surrounding Androgen Deprivation Therapy and Cognitive Dysfunction.",
"datePublished": "2023-03-31",
"url": "https://questionsmedicales.fr/article/37005166",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.euf.2023.03.015"
}
},
{
"@type": "ScholarlyArticle",
"name": "Neuroanatomical Correlates of Cognitive Dysfunction in 22q11.2 Deletion Syndrome.",
"datePublished": "2024-03-30",
"url": "https://questionsmedicales.fr/article/38674375",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/genes15040440"
}
},
{
"@type": "ScholarlyArticle",
"name": "Sex differences in the effects of sleep disorders on cognitive dysfunction.",
"datePublished": "2023-01-27",
"url": "https://questionsmedicales.fr/article/36716906",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.neubiorev.2023.105067"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Transferases",
"item": "https://questionsmedicales.fr/mesh/D014166"
},
{
"@type": "ListItem",
"position": 5,
"name": "Acyltransferases",
"item": "https://questionsmedicales.fr/mesh/D000217"
},
{
"@type": "ListItem",
"position": 6,
"name": "Carnitine acyltransferases",
"item": "https://questionsmedicales.fr/mesh/D002333"
},
{
"@type": "ListItem",
"position": 7,
"name": "Carnitine O-palmitoyltransferase",
"item": "https://questionsmedicales.fr/mesh/D002334"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Carnitine O-palmitoyltransferase - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Carnitine O-palmitoyltransferase",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Carnitine O-palmitoyltransferase",
"description": "Comment diagnostiquer une déficience en carnitine O-palmitoyltransférase ?\nQuels tests sont utilisés pour évaluer l'activité de l'enzyme ?\nQuels symptômes peuvent indiquer un problème avec cette enzyme ?\nLes tests de dépistage néonatal incluent-ils cette enzyme ?\nQuelle imagerie peut aider au diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D002334?mesh_terms=Cognitive+Dysfunction&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Carnitine O-palmitoyltransferase",
"description": "Quels sont les symptômes courants d'une déficience en carnitine O-palmitoyltransférase ?\nLa déficience peut-elle causer des problèmes cardiaques ?\nLes symptômes varient-ils selon l'âge ?\nY a-t-il des signes d'alerte à surveiller ?\nLes symptômes peuvent-ils apparaître après un effort physique ?",
"url": "https://questionsmedicales.fr/mesh/D002334?mesh_terms=Cognitive+Dysfunction&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Carnitine O-palmitoyltransferase",
"description": "Peut-on prévenir la déficience en carnitine O-palmitoyltransférase ?\nLes femmes enceintes doivent-elles être testées ?\nY a-t-il des conseils diététiques pour les familles à risque ?\nLes vaccinations sont-elles importantes pour ces patients ?\nComment surveiller les symptômes chez les enfants ?",
"url": "https://questionsmedicales.fr/mesh/D002334?mesh_terms=Cognitive+Dysfunction&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Carnitine O-palmitoyltransferase",
"description": "Quel est le traitement principal pour cette déficience ?\nDes modifications alimentaires sont-elles nécessaires ?\nLes médicaments peuvent-ils aider ?\nLa thérapie physique est-elle bénéfique ?\nY a-t-il des traitements expérimentaux disponibles ?",
"url": "https://questionsmedicales.fr/mesh/D002334?mesh_terms=Cognitive+Dysfunction&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Carnitine O-palmitoyltransferase",
"description": "Quelles complications peuvent survenir avec cette déficience ?\nLa déficience peut-elle entraîner des crises ?\nY a-t-il un risque accru de maladies métaboliques ?\nLes complications sont-elles réversibles ?\nComment prévenir les complications graves ?",
"url": "https://questionsmedicales.fr/mesh/D002334?mesh_terms=Cognitive+Dysfunction&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Carnitine O-palmitoyltransferase",
"description": "Quels sont les facteurs de risque pour cette déficience ?\nLes nourrissons sont-ils plus à risque ?\nLes personnes obèses sont-elles plus susceptibles d'être affectées ?\nY a-t-il des facteurs environnementaux à considérer ?\nLes maladies chroniques augmentent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D002334?mesh_terms=Cognitive+Dysfunction&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en carnitine O-palmitoyltransférase ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic se fait par des tests génétiques et des analyses sanguines pour mesurer les niveaux de carnitine."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité de l'enzyme ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques dans des échantillons de tissus ou de sang peuvent être réalisés."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec cette enzyme ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la fatigue, la faiblesse musculaire et des douleurs peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les tests de dépistage néonatal incluent-ils cette enzyme ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains programmes de dépistage néonatal incluent des tests pour les troubles métaboliques."
}
},
{
"@type": "Question",
"name": "Quelle imagerie peut aider au diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'IRM peut être utilisée pour évaluer les dommages musculaires associés à la déficience."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants d'une déficience en carnitine O-palmitoyltransférase ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, faiblesse musculaire, hypoglycémie et douleurs musculaires."
}
},
{
"@type": "Question",
"name": "La déficience peut-elle causer des problèmes cardiaques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications cardiaques peuvent survenir en raison d'une mauvaise utilisation des acides gras."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent être plus graves chez les nourrissons que chez les adultes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes d'alerte à surveiller ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des crises, une faiblesse extrême ou des troubles respiratoires doivent alerter."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils apparaître après un effort physique ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice intense peut déclencher des symptômes chez les personnes atteintes."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la déficience en carnitine O-palmitoyltransférase ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un dépistage précoce peut aider à gérer la condition."
}
},
{
"@type": "Question",
"name": "Les femmes enceintes doivent-elles être testées ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le dépistage peut être recommandé si des antécédents familiaux existent."
}
},
{
"@type": "Question",
"name": "Y a-t-il des conseils diététiques pour les familles à risque ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une consultation avec un nutritionniste peut aider à établir un régime adapté."
}
},
{
"@type": "Question",
"name": "Les vaccinations sont-elles importantes pour ces patients ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccinations sont cruciales pour prévenir les infections qui peuvent aggraver la condition."
}
},
{
"@type": "Question",
"name": "Comment surveiller les symptômes chez les enfants ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les parents doivent surveiller la fatigue, les douleurs musculaires et consulter un médecin."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal pour cette déficience ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement principal consiste en des suppléments de carnitine pour compenser le déficit."
}
},
{
"@type": "Question",
"name": "Des modifications alimentaires sont-elles nécessaires ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un régime riche en glucides et faible en graisses peut être recommandé."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils aider ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments peuvent être prescrits pour gérer les symptômes et prévenir les complications."
}
},
{
"@type": "Question",
"name": "La thérapie physique est-elle bénéfique ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la thérapie physique peut aider à améliorer la force musculaire et la fonction."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux disponibles ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des essais cliniques peuvent explorer de nouvelles thérapies, mais ils sont limités."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec cette déficience ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles musculaires, des problèmes cardiaques et des hypoglycémies."
}
},
{
"@type": "Question",
"name": "La déficience peut-elle entraîner des crises ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des crises peuvent survenir en raison d'une hypoglycémie sévère ou d'un stress métabolique."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de maladies métaboliques ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients peuvent être à risque accru de développer d'autres maladies métaboliques."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications graves ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier et une gestion appropriée des symptômes sont essentiels."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour cette déficience ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux de troubles métaboliques augmentent le risque de déficience."
}
},
{
"@type": "Question",
"name": "Les nourrissons sont-ils plus à risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les nourrissons, surtout ceux avec des antécédents familiaux, sont plus à risque."
}
},
{
"@type": "Question",
"name": "Les personnes obèses sont-elles plus susceptibles d'être affectées ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'obésité peut augmenter le risque de troubles métaboliques, y compris cette déficience."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux à considérer ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs comme l'alimentation et l'exposition à des toxines peuvent influencer le risque."
}
},
{
"@type": "Question",
"name": "Les maladies chroniques augmentent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies chroniques peuvent prédisposer à des troubles métaboliques."
}
}
]
}
]
}
Cognitive dysfunction is one of the criteria for the diagnosis of fibromyalgia (FM) and is typically based on self-report questionnaires such as the Symptom Severity Scale. However, recent studies hav...
Sixty-two FM patients (55 women, 7 men, mean age = 46.17 years, sd=12.56) were administered the MoCA and a computerised cognitive assessment battery. FM symptoms were assessed on the Fibromyalgia Impa...
Moderate positive correlations were found between the MoCA and the computerised cognitive scores as follows: Global Cognitive Score (r=0.493**, p=0.00), Memory Index Score (r= 0.384**, p=0.002), Execu...
The MoCA is an acceptable cognitive screening test for the cognitive evaluation of FM patients....
Cognitive dysfunction is an important non-motor symptom in amyotrophic lateral sclerosis (ALS) that has a negative impact on survival and caregiver burden. It shows a wide spectrum ranging from subjec...
There are varied associations that have been identified between the use of androgen deprivation therapy (ADT) and the development of cognitive decline. We highlight the first studies to evaluate chron...
22q11.2 Deletion Syndrome (22q11.2DS), the most common chromosomal microdeletion, presents as a heterogeneous phenotype characterized by an array of anatomical, behavioral, and cognitive abnormalities...
Sleep is an essential physiological function that sustains human life. Sleep disorders involve problems with the quality, duration, and abnormal behaviour of sleep. Insomnia is the most common sleep d...
Previous studies have shown that multimorbidity is a risk factor for cognitive dysfunction (CD).Type 2 diabetes mellitus (T2DM) and hypertension (HT) are very common risk factors.The association betwe...
To evaluate the association between multimorbidity due to T2DM and HT with CD among adults ≥50 years in Tumbes....
A secondary analysis of a population-based cross-sectional study was conducted. The exposure variable was the presence of both T2DM and HT, split into categories: without HT or T2DM, only T2DM, only H...
688 participants were analyzed. The prevalence of CD was 39.1%. There was a 56.1% of participants without TDM2 nor HT, 8.3% with T2DM, 28.9% with HT and 6.7% with both diseases. A significant associat...
There is association between the morbidity of T2DM and HT, and CD among adults ≥50 years of age in Tumbes. Education was an effect modifier of the association between HT and T2DM on the presence of CD...
Type 2 diabetes (T2DM) is a well known risk factor for Alzheimer's disease. Mitochondria are the center of intracellular energy metabolism and the main source of reactive oxygen species. Mitochondrial...
This review provides an overview of obsessive-compulsive disorder (OCD) symptoms, including the four partially distinct subtypes of the disorder, current diagnostic criteria, and common comorbidities....
This review study was conducted by library method....
We show how dysfunction in cortico-striato-thalamo-cortical (CSTC) circuits may underpin symptoms; and shed light on the putative neurochemistry within these loops such as the role of serotonin, dopam...
In brief, research questions we shed light on include (1) what are the symptoms in OCD; (2) what is the etiology of the disorder and do existing models explain OCD; and (3) what are key cognitive defi...
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease, in which cognitive dysfunction is common, but poorly understood. This study aims to characterize the prevalence and patterns of cogn...
SLE patients (...
The SLE group performed significantly worse than healthy controls on every cognitive test. The largest differences were in the domains of verbal fluency, working memory and attention, while fine motor...
Cognitive dysfunction is common in SLE but markedly heterogeneous across both cognitive domains and across the SLE group. Cluster analysis supports the use of a binary definition of cognitive dysfunct...
A growing body of literature suggests the important role of the thalamus in cognition and neurodegenerative diseases. This study aims to elucidate whether the preoperative thalamic volume is associate...